🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Anhui Provincial Cancer Hospital clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Anhui Provincial Cancer Hospital as lead sponsor. Synced 26 Sep 2026
15Current trials
8Recruiting now
8Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Anhui Provincial Cancer Hospital is the lead sponsor of 15 current clinical trials in our China register. 8 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Paclitaxel, Becotatug Vedotin and Carboplatin. The most-studied condition is Ovarian Cancer.

ClinicalTrials.gov trials by status

  • Recruiting853%
  • Not yet open533%
  • Active, closed213%

Trials by phase

  • Phase 2853%
  • Phase 1/2320%
  • Observational213%
  • Not applicable17%
  • Phase 417%
01

Clinical trials sponsored by Anhui Provincial Cancer Hospital

15 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
To Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung Cancer
NCT07195084 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer
Not applicable Recruiting 2025-09 China
QL1706 Combined With Chemotherapy in the Treatment of Immune-mediated NSCLC
NCT07330596 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer)
Phase 2 Recruiting 2025-10 China
Noninvasive Real-Time Arterial Waveform Monitoring for Cardiovascular Disease Assessment
NCT07350629 · ClinicalTrials.gov ↗ · Aortic Regurgitation Disease, Aortic Stenosis Disease, Healthy Subjects
Observational Recruiting 2025-12 China
Low Dose Radiotherapy Combined With Sintilimab and Chemotherapy as Neoadjuvant Therapy for Stage II-III NSCLC
NCT06714708 · ClinicalTrials.gov ↗ · NSCLC, Neoadjuvant Immunotherapy, Low Dose Radiotherapy
Phase 2 Recruiting 2024-11 China
Tislelizumab Combined With Chemotherapy and Relayed Radiotherapy in First-line Treatment of ES-SCLC
NCT06838208 · ClinicalTrials.gov ↗ · Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Phase 2 Recruiting 2025-02 China
Surufatinib Combined With Carboplatin/Paclitaxel and Surufatinib Combined With Olaparib as First-line and Maintenance Therapy for Newly Diagnosed High-risk Ovarian Cancer
NCT06437353 · ClinicalTrials.gov ↗ · Ovarian Cancer
Phase 2 Recruiting 2024-05 China
Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer
NCT06395844 · ClinicalTrials.gov ↗ · Ovarian Cancer
Phase 1/2 Recruiting 2024-05 China
Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)
NCT07744698 · ClinicalTrials.gov ↗ · Squamous Non-Small Cell Lung Cancer sqNSCLC, Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Phase 4 Recruiting 2026-07 China
Super-Resolution Ultrasound Imaging for Assessing Response to Neoadjuvant Chemotherapy in Breast Cancer
NCT07623226 · ClinicalTrials.gov ↗ · Breast Cancer
Observational Not yet open 2026-06 China
A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer
NCT07661173 · ClinicalTrials.gov ↗ · Non Small Cell Lung Cancer
Phase 2 Not yet open 2026-06 China
Sintilimab Plus Bevacizumab and Chemotherapy in MSS/pMMR Colorectal With no Liver Metastasis
NCT06973343 · ClinicalTrials.gov ↗ · Colorectal Cancer Metastatic
Phase 2 Not yet open 2025-05 China
Becotatug Vedotin Combined With Pucotenlimab ± Radiotherapy as First-Line Treatment for Driver-Gene-Negative, EGFR-Expression-Positive Advanced Non-Small Cell Lung Cancer
NCT07627321 · ClinicalTrials.gov ↗ · NSCLC (Advanced Non-small Cell Lung Cancer)
Phase 2 Not yet open 2026-07 China
SHR-1811 Combined With Carboplatin in the Treatment of Advanced Breast Cancer With HER2 Expression
NCT07047443 · ClinicalTrials.gov ↗ · Breast Cancer
Phase 2 Not yet open 2025-08 China
An Exploratory Study on NK Cell-assisted Prevention of Bone Marrow Suppression During Chemotherapy for Ovarian Cancer
NCT07096583 · ClinicalTrials.gov ↗ · Ovary Cancer
Phase 1/2 Active, closed 2025-07 China
METR-NK Cells in Combination With Anti-angiogenic Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer
NCT06884345 · ClinicalTrials.gov ↗ · Ovarian Cancer
Phase 1/2 Active, closed 2025-03 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Anhui Provincial Cancer Hospital trials

8 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Anhui Provincial Cancer Hospital trials

16 conditions
Ovarian Cancer3Breast Cancer2NSCLC (Advanced Non-small Cell Lung Cancer)2Extensive-stage Small Cell Lung Cancer (ES-SCLC)2Non-Small Cell Lung Cancer1Aortic Regurgitation Disease1Aortic Stenosis Disease1Healthy Subjects1Non Small Cell Lung Cancer1Colorectal Cancer Metastatic1NSCLC1Neoadjuvant Immunotherapy1Low Dose Radiotherapy1Sintilimab1Ovary Cancer1Squamous Non-Small Cell Lung Cancer sqNSCLC1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China158

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Ovarian Cancer

SponsorTrials
Tongji Hospital7
Xencor3
Hangzhou SynRx Therapeutics Biomedical Technology3
Genmab2
Tubulis2
USWM CT2
BeiGene2
Imunon2
CanariaBio2
Chongqing University Cancer Hospital2

Sponsors with the most current trials registered for this condition.

06

Questions about Anhui Provincial Cancer Hospital trials

How many clinical trials does Anhui Provincial Cancer Hospital sponsor?

Anhui Provincial Cancer Hospital is the lead sponsor of 15 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Anhui Provincial Cancer Hospital trials recruiting?

Yes. 8 of its 15 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Anhui Provincial Cancer Hospital testing?

Its current trials name 8 drugs and biologicals as interventions. The most frequent are Paclitaxel (2), Becotatug Vedotin (1), Carboplatin (1), Furmonertinib (1) and Iparomlimab and Tuvonralimab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.